参麦及舒血宁注射液佐治急性心肌梗塞的临床观察

目的:探讨无PTCA、溶栓适应证急性心肌梗塞(AMI)患者的有效治疗方法。方法:80例AMI患者随机分为:参麦 舒血宁组(27例,在常规治疗基础上增加参麦注射液治疗,2周,继以口服治疗2周),舒血宁组(26例,在常规治疗基础上增加舒血宁注射液治疗,2周,继以口服治疗2周),(常规治疗)对照组(27例,予以低分子肝素等常规治疗治疗4周)。结果:参麦 舒血宁组心力衰竭、心律失常、病死率较对照组显著减少(P<0.05～<0.01),高血糖症较舒血宁组显著减少(P<0.05);舒血宁组心力衰竭和心律失常较对照组显著减少(P<0.05)。结论:参麦 舒血宁治疗急性心肌梗塞可减少合并症、死亡率,疗效优于常规对照组,也优于舒血宁 常规治疗。

Effects of danshen root and maidong in patients with acute myocardium infarction

Objective:To study the effective therapeutic method in patients with acute myocardium infarction(AMI) without indication of PTCA and thrombolysis.Methods:A total of 80 patients were randomly divided into: danshen root maidong (danmai) and shuxuening group (group A, 27 cases, treated with danmai and shuxuening above routine therapy), shuxuening group (group B, 26 cases, treated with shuxuening above routine therapy) and (routine therapy)control group (group C, 26 cases, treated with routine therapy), the time of therapy was four weeks all.Results:The cardiac failure, arrhythmia and mortality of group A were significantly decreased compared with group C (P<0.05~<0.01). The patients with hyperglucemia of group A were less than those of group B (P<0.05). The cardiac failure and arrhythmia of group B significantly decreased compared with group C (P<0.05).Conclusion:Danmai and shuxuening therapy may decrease complication and mortality in AMI patients.